JWCA
HCWB icon

J.W. Cole Advisors’s HCW Biologics HCWB Stock Holding History

J.W. Cole Advisors’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,083
Closed -$12.1K – 1050
2025
Q4 		$12.1K Buy
+2,083
New +$35.4K ﹤0.01% 1447
2025
Q2 		– Sell
-223
Closed -$15.1K – 1474
2025
Q1 		$15.1K Buy
+223
New +$19.6K ﹤0.01% 1247

Other funds holding HCWB

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

J.W. Cole Advisors's HCWB Position: Q1 2026 in Review

J.W. Cole Advisors sold out of HCW Biologics (HCWB) in Q1 2026, closing a stake of 2,083 shares — an estimated $12.1K sold.

J.W. Cole Advisors first reported a position in HCWB in Q1 2025 and held it in 2 quarters. The position peaked at $15.1K in Q1 2025. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

  • J.W. Cole Advisors reported no remaining HCW Biologics position as of Q1 2026 after selling out during the quarter.
  • J.W. Cole Advisors sold 2,083 HCW Biologics shares in Q1 2026, an estimated $12.1K.
  • J.W. Cole Advisors first reported a position in HCW Biologics in Q1 2025 and held it in 2 quarters.
  • J.W. Cole Advisors's HCW Biologics position peaked at $15.1K in Q1 2025.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on J.W. Cole Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.